Studies suggest tirzepatide may help improve cardiometabolic risk factors and reduce the risk of atherosclerotic cardiovascular disease (CVD)
Gastrointestinal side effects are the most frequently reported experiences in the first few weeks
74 Besides the expected improvements in metabolism and hepatic steatosis, liver fibrosis markers, including the fibrosis-4 index, ferritin, and type IV collagen 7s, were observed to decrease after 24 weeks of treatment
The researchers included 30 obese patients in a randomized, double-blind, placebo-controlled, two-period crossover experiment over a 12-week period to accomplish this
Your dose may need to go up as your body adjusts to treatment
Your body processes these medications slowly